Although the cardiovascular benefits of using GLP-1 RAs for diabetic patients have been well-documented [9], there was previously a paucity of evidence for using these agents for cardiovascular risk reduction in nondiabetic overweight/obesity. Here, GLP1R is linked to Obesity.